Avasimibe Pfizer

Curr Opin Investig Drugs. 2002 Sep;3(9):1328-33.

Abstract

Avasimibe (also known as CI-1011 or PD-148515) is a selective acyl-coenzyme A:cholesterol O-acyltransferase (ACAT) inhibitory lipid-regulating agent under development by Pfizer (formerly Parke-Davis) for the potential treatment of hyperlipidemia and atherosclerosis. The compound is currently undergoing phase III clinical trials [371470].

Publication types

  • Review

MeSH terms

  • Acetamides
  • Acetates / chemistry
  • Acetates / pharmacology
  • Acetates / therapeutic use*
  • Animals
  • Arteriosclerosis / drug therapy
  • Arteriosclerosis / enzymology
  • Clinical Trials as Topic / methods
  • Clinical Trials as Topic / statistics & numerical data
  • Drug Industry / legislation & jurisprudence
  • Drug Industry / methods*
  • Enzyme Inhibitors / chemistry
  • Enzyme Inhibitors / pharmacology
  • Enzyme Inhibitors / therapeutic use
  • Humans
  • Hyperlipidemias / drug therapy
  • Hyperlipidemias / enzymology
  • Sulfonamides
  • Sulfonic Acids / chemistry
  • Sulfonic Acids / pharmacology
  • Sulfonic Acids / therapeutic use*

Substances

  • Acetamides
  • Acetates
  • Enzyme Inhibitors
  • Sulfonamides
  • Sulfonic Acids
  • avasimibe